• Citer

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.

par Datoo, Mehreen MS;Natama, Hamtandi Magloire;Somé, Athanase;Traoré, Ousmane;Rouamba, Toussaint ;Bellamy, Duncan;Yameogo, Prisca;Valia, Daniel;Tegneri, Moubarak;Ouedraogo, Florence;Soma, Rachidatou;Sawadogo, Seydou;Sorgho, Faizatou;Derra, Karim;Rouamba, Eli;Orindi, Benedict;Ramos Lopez, Fernando;Flaxman, Amy;Cappuccini, Federica;Kailath, Reshma;Elias, Sean;Mukhopadhyay, Ekta;Noe, Andres;Cairns, Matthew;Lawrie, Alison;Roberts, Rachel;Valéa, Innocent;Sorgho, Hermann;Williams, Nicola;Glenn, Gregory;Fries, Louis;Reimer, Jenny;Ewer, Katie KJ;Shaligram, Umesh;Hill, Adrian V S;Tinto, Halidou
Référence Lancet, 397, 10287, page (1809-1818)
Publication Publié, 2021-05-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Stalled progress in controlling Plasmodium falciparum malaria highlights the need for an effective and deployable vaccine. RTS,S/AS01, the most effective malaria vaccine candidate to date, demonstrated 56% efficacy over 12 months in African children. We therefore assessed a new candidate vaccine for safety and efficacy.